PPARGC1A and chronic kidney disease: This is the first study to demonstrate that PF has therapeutic potential on CKD skeletal muscle atrophy through the AMPK/SIRT1/PGC-1α-mediated ubiquitin–proteasome system (UPS), inflammation, oxidative stress and mitochondrial dysfunction.